Apoptosis regulation in onset, progression and therapy of oncological diseases
Submission Deadline: 30 Jun 2022
Guest Editors

Department of Pharmacy, University "G. d'Annunzio", Chieti-Pescara, Italy
Interests: Biomaterials; Bone regeneration; Stem cells; Oxidative stress; Apoptosis; Neuroprotection; Antitumoral drugs; Cell culture; In vitro systems; Flow cytometry
Department of Medicine and Aging Sciences University “G. d’Annunzio” Chieti-Pescara, Italy
Interests: Biomaterials; Scaffolds; Bone Regeneration; Stem Cells; Apoptosis; Aging; Molecular Biology; Cell Signaling
Special Issue Information
Dear Colleagues,
Apoptosis is a finely regulated cellular process in tissue homeostasis and acts predominantly during embryonic development. In this delicate phase, the deletion of redundant cellular material is necessary for the correct morphogenesis of tissues and organs; but apoptosis is also an indispensable process for the maintenance of tissue homeostasis during the entire cell life.
Furthermore, apoptosis can also be triggered in pathological conditions, where the removal of cells undergoing damage to DNA and/or cellular organelles is essential for maintaining the health of organisms. Hence, the comprehension of the regulation of apoptotic pathways can help in the development of new promising therapeutic approaches.
Oncological diseases are characterized by an imbalance between cell division and cell death. Consequently, cells that should die continue to proliferate. The error that leads to this situation can occur anywhere during the apoptotic pathway.
Cancer can indeed be thought of as the product of successive genetic errors that lead to the formation of a malignant cell and the escape from cell death is one of the fundamental changes that cause this malignant transformation. Therefore, an impairment of the apoptotic process plays a fundamental role in carcinogenesis and can occur in different ways:
· imbalance between apoptotic and anti-apoptotic proteins (e.g. Bcl-2, p53, IAPs)
· reduced or non-functioning caspases (initiator caspase e.g.-2, -8, -9, -10; effector caspase e.g. -3, -6, -7)
· impaired death receptor signaling (e.g. TNFR1, Fas, TRAIL).
This Special Issue is focused on the role of apoptosis in oncological diseases and its purpose is the investigation of the physico-chemical stimuli regulating the apoptotic process and the molecular mechanisms at the basis of apoptosis imbalance in cancer onset and progression. The research of novel therapeutic targets and approaches in cancer fits within the aims of the special issue as well.
The guest-editors invite authors to submit original research and review articles related to any of these aspects.
Assoc. Prof. Viviana di Giacomo and Assoc. Prof. Silvia Sancilio
Guest Editors
Keywords
- Apoptosis
- Cancer
- Regulation
- Molecular Mechanism(s)
- Impairment
- Therapeutic Approach
- Target
- Pathways
- Caspases
Published Papers (2)
The Role of Epigenetic Regulator SIRT1 in Balancing the Homeostasis and Preventing the Formation of Specific “Soil” of Metabolic Disorders and Related Cancers
Front. Biosci. (Landmark Ed) 2022, 27(9), 253; https://doi.org/10.31083/j.fbl2709253
(This article belongs to the Special Issue Apoptosis regulation in onset, progression and therapy of oncological diseases)
Tumor-Suppressor Gene Transmembrane Protein 98 Promotes Proliferation and Inhibits Apoptosis in Ovarian Cancer
Front. Biosci. (Landmark Ed) 2022, 27(7), 210; https://doi.org/10.31083/j.fbl2707210
(This article belongs to the Special Issue Apoptosis regulation in onset, progression and therapy of oncological diseases)
